Effet de l'inhibition chronique de la synthèse du monoxyde d'azote sur la pression artérielle et l'apparition des dommages cardiovasculaires et rénaux chez le rat Harlan Sprague-Dawley

BIBLIOGRAPHIE

1. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens. 1997;10:1097-102.

2. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14:83-90.

3. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-7.

4. Pachori AS, Huentelman MJ, Francis SC, Gelband CH, Katovich MJ, Raizada MK. The future of hypertension therapy: sense, antisense, or nonsense? Hypertension. 2001;37:357-64.

5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.

6. Joffres MR, Hamet P, MacLean DR, L'Italien G J, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens. 2001;14:1099-105.

7. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-13.

8. Tortora GJ GS. Principes d'anatomie et de physiologie; 2001.

9. Laragh JH BB. Hypertension: Raven Press; 1990.

10. Rector's B. The kidney. Fifth Edition ed; 1996.

11. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:77-84.

12. Goldstein DS. Plasma norepinephrine in essential hypertension. A study of the studies. Hypertension. 1981;3:48-52.

13. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension. 1983;5:86-99.

14. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.

15. Halcox JQ, A. Endothelial function and cardiovascular disease. In: American Heart Association; 2003.

16. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-92.

17. Panza JA, Quyyumi AA, Brush JE, Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-7.

18. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-7.

19. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986;250:H822-7.

20. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-9.

21. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.

22. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-6.

23. Ignarro LJ, Buga GM, Byrns RE, Wood KS, Chaudhuri G. Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial and venous smooth muscle. J Pharmacol Exp Ther. 1988;246:218-26.

24. Gabbai FB, Garcia GE, Blantz RC, De Nicola L. Role of nitric oxide in glomerular physiology and pathophysiology. Adv Nephrol Necker Hosp. 1995;24:3-18.

25. Andrews KL, Triggle CR, Ellis A. NO and the vasculature: where does it come from and what does it do? Heart Fail Rev. 2002;7:423-45.

26. Schroeder RA, Kuo PC. Nitric oxide: physiology and pharmacology. Anesth Analg. 1995;81:1052-9.

27. Ujiie K, Yuen J, Hogarth L, Danziger R, Star RA. Localization and regulation of endothelial NO synthase mRNA expression in rat kidney. Am J Physiol. 1994;267:F296-302.

28. Vanhoutte PM. Vascular Nitric Oxide; 2003.

29. Dumont Y, D'Amours M, Lebel M, Lariviere R. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol Dial Transplant. 2001;16:746-54.

30. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension. 1998;32:958-64.

31. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375-8.

32. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 1992;20:298-303.

33. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278-81.

34. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: the role of superoxide anion. Hypertension. 1999;34:539-45.

35. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. J Pathol. 2003;199:8-17.

36. D'Amours M, Lebel M, Grose JH, Lariviere R. Renal and vascular effects of chronic nitric oxide synthase inhibition: involvement of endothelin 1 and angiotensin II. Can J Physiol Pharmacol. 1999;77:8-16.

37. Van Dokkum RP, Jacob HJ, Provoost AP. Genetic differences define severity of renal damage after L-NAME-induced hypertension in rats. J Am Soc Nephrol. 1998;9:363-71.

38. Jover B, Herizi A, Ventre F, Dupont M, Mimran A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension. 1993;21:944-8.

39. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension. 1993;21:660-6.

40. Vidal MJ, Romero JC, Vanhoutte PM. Endothelium-derived relaxing factor inhibits renin release. Eur J Pharmacol. 1988;149:401-2.

41. Tharaux PL, Dussaule JC, Pauti MD, Vassitch Y, Ardaillou R, Chatziantoniou C. Activation of renin synthesis is dependent on intact nitric oxide production. Kidney Int. 1997;51:1780-7.

42. Garcia GE, Brown MR, Wead LM, Braun S, Gabbai FB. Effect of reduction of nitric oxide on plasma and kidney tissue angiotensin II levels. Am J Hypertens. 1997;10:1103-8.

43. Conrad KP, Whittemore SL. NG-monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats. Am J Physiol. 1992;262:R1137-44.

44. Qiu C, Engels K, Baylis C. Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol. 1994;266:R1470-6.

45. Tojo A, Kobayashi N, Kimura K, Hirata Y, Matsuoka H, Yagi S, Omata M. Effects of antihypertensive drugs on nitric oxide synthase activity in rat kidney. Kidney Int Suppl. 1996;55:S138-40.

46. Kung CF, Moreau P, Takase H, Luscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Hypertension. 1995;26:744-51.

47. Ribeiro MO, Antunes E, Muscara MN, De Nucci G, Zatz R. Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension. 1995;26:150-5.

48. Erley CM, Rebmann S, Strobel U, Schmidt T, Wehrmann M, Osswald H, Risler T. Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp Nephrol. 1995;3:293-9.

49. Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int. 1996;49:1727-31.

50. Mattson DL, Wu F. Control of arterial blood pressure and renal sodium excretion by nitric oxide synthase in the renal medulla. Acta Physiol Scand. 2000;168:149-54.

51. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl. 1998;68:S14-9.

52. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.

53. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003;144:2179-83.

54. Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol. 2003;35:759-68.

55. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986;78:31-9.

56. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87:1816-28.

57. van den Eijnden MM, de Bruin RJ, de Wit E, Sluiter W, Deinum J, Reudelhuber TL, Danser AH. Transendothelial transport of renin-angiotensin system components. J Hypertens. 2002;20:2029-37.

58. Skidgel REE. Angiotensin I converting enzyme and neprilysin (neutral endopeptidase); 2003.

59. Phillips M. Tissue Renin-Angiotensin Systems; 2003.

60. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol. 1995;11 Suppl F:13F-19F.

61. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Hohle S, Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens Suppl. 1996;14:S95-103.

62. Goodfriend TL. Angiotensins : Actions and Receptors. In; 2003.

63. Touyz RM. Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens. 2003;12:165-74.

64. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-52.

65. Fakhouri F, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol. 2001;12:2701-10.

66. Scott-Burden T, Resink TJ, Hahn AW, Vanhoutte PM. Induction of endothelin secretion by angiotensin II: effects on growth and synthetic activity of vascular smooth muscle cells. J Cardiovasc Pharmacol. 1991;17 Suppl 7:S96-100.

67. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999;43:300-7.

68. Dumont Y, D'Amours M, Lebel M, Lariviere R. Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J Hypertens. 2001;19:1479-87.

69. Carey RM, Wang ZQ, Siragy HM. Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation. Curr Hypertens Rep. 2000;2:198-201.

70. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab. 2000;11:1-6.

71. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377:744-7.

72. Akishita M, Yamada H, Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun. 1999;261:345-9.

73. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A. 1999;96:6506-10.

74. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-5.

75. D'Orleans-Juste P, Plante M, Honore JC, Carrier E, Labonte J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol. 2003;81:503-10.

76. Schiffrin EL. Endothelin; 2003.

77. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81:607-21.

78. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290-301.

79. Matsushima H, Yamada N, Matsue H, Shimada S. The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. Eur J Immunol. 2004;34:1910-9.

80. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther. 2002;95:221-38.

81. Brochu E, Lacasse S, Moreau C, Lebel M, Kingma I, Grose JH, Lariviere R. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant. 1999;14:1881-8.

82. Schiffer M, von Gersdorff G, Bitzer M, Susztak K, Bottinger EP. Smad proteins and transforming growth factor-beta signaling. Kidney Int Suppl. 2000;77:S45-52.

83. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med. 2004;82:175-81.

84. Touyz RM. Reactive Oxygen Species and Mediators of Oxidative Stress; 2003.

85. Marx. Rosen's emergency medicine : concepts and clinical practice. 5th ed; 2002.

86. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53:1748-54.

87. de Gasparo M. Angiotensin II and nitric oxide interaction. Heart Fail Rev. 2002;7:347-58.

88. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens. 1993;11:1083-8.

89. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J Clin Invest. 1992;89:1248-56.

90. Fortepiani LA, Ruiz MC, Passardi F, Bentley MD, Garcia-Estan J, Ritman EL, Romero JC. Effect of losartan on renal microvasculature during chronic inhibition of nitric oxide visualized by micro-CT. Am J Physiol Renal Physiol. 2003;285:F852-60.

91. Cahill PA, Redmond EM, Foster C, Sitzmann JV. Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. Eur J Pharmacol. 1995;288:219-29.

92. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 1998;83:743-51.

93. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev. 2003;8:107-15.

94. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-90.

95. Lerman A, Sandok EK, Hildebrand FL, Jr., Burnett JC, Jr. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation. 1992;85:1894-8.

96. Banting JD, Friberg P, Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J Hypertens. 1996;14:975-81.

97. Moreau P, Takase H, Kung CF, Shaw S, Luscher TF. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension. 1997;29:763-9.

98. Kim S, Ohta K, Hamaguchi A, Omura T, Tominaga K, Yukimura T, Miura K, Tanaka M, Iwao H. AT1 receptor-mediated stimulation by angiotensin II of rat aortic fibronectin gene expression in vivo. Br J Pharmacol. 1994;113:662-3.

99. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 1994;74:727-39.

100. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-4.

101. Harisson DG, Griendling, K.K. Oxidative Stress and Hypertension; 2003.

102. Pollock DM, Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Am J Physiol. 1998;275:R1719-23.

103. Lariviere R, Lebel M, Kingma I, Grose JH, Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens. 1998;11:989-97.

104. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, Goto H, Okuda S, Fujishima M. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol. 2000;11:616-24.

105. Moini H, Packer L, Saris NE. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol. 2002;182:84-90.

106. Takaoka M, Kobayashi Y, Yuba M, Ohkita M, Matsumura Y. Effects of alpha-lipoic acid on deoxycorticosterone acetate-salt-induced hypertension in rats. Eur J Pharmacol. 2001;424:121-9.

107. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension. 2002;39:303-7.

108. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. 2000;18:567-73.


Collection Mémoires et thèses électroniques
Accueil À propos Nous joindre


CONCLUSION